CA2436540C - Composition pharmaceutique a base d'anticholinergiques et de corticosteroides - Google Patents

Composition pharmaceutique a base d'anticholinergiques et de corticosteroides Download PDF

Info

Publication number
CA2436540C
CA2436540C CA002436540A CA2436540A CA2436540C CA 2436540 C CA2436540 C CA 2436540C CA 002436540 A CA002436540 A CA 002436540A CA 2436540 A CA2436540 A CA 2436540A CA 2436540 C CA2436540 C CA 2436540C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition according
inhalable
propellant
tiotropium bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002436540A
Other languages
English (en)
Other versions
CA2436540A1 (fr
Inventor
Michel Pairet
Michael Paul Pieper
Christopher John Montague Meade
Richard Reichl
Christel Schmelzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10062712A external-priority patent/DE10062712A1/de
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to CA2614631A priority Critical patent/CA2614631C/fr
Publication of CA2436540A1 publication Critical patent/CA2436540A1/fr
Application granted granted Critical
Publication of CA2436540C publication Critical patent/CA2436540C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002436540A 2000-10-31 2001-10-23 Composition pharmaceutique a base d'anticholinergiques et de corticosteroides Expired - Fee Related CA2436540C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2614631A CA2614631C (fr) 2000-10-31 2001-10-23 Compositions pharmaceutiques contenant des anticholinergiques et des corticosteroides sous la forme d'une suspension ou d'une solution inhalable

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31
DE10054042.2 2000-10-31
DE10062712.9 2000-12-15
DE10062712A DE10062712A1 (de) 2000-12-15 2000-12-15 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
PCT/EP2001/012511 WO2002036106A2 (fr) 2000-10-31 2001-10-23 Nouvelle composition medicamenteuse a base d'anticholinergiques et de corticosteroides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2614631A Division CA2614631C (fr) 2000-10-31 2001-10-23 Compositions pharmaceutiques contenant des anticholinergiques et des corticosteroides sous la forme d'une suspension ou d'une solution inhalable

Publications (2)

Publication Number Publication Date
CA2436540A1 CA2436540A1 (fr) 2002-05-10
CA2436540C true CA2436540C (fr) 2008-01-29

Family

ID=26007540

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2733294A Expired - Fee Related CA2733294C (fr) 2000-10-31 2001-10-23 Combinaison pharmaceutique constituee d'un sel de tiotropium et de ciclesonide
CA002436540A Expired - Fee Related CA2436540C (fr) 2000-10-31 2001-10-23 Composition pharmaceutique a base d'anticholinergiques et de corticosteroides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2733294A Expired - Fee Related CA2733294C (fr) 2000-10-31 2001-10-23 Combinaison pharmaceutique constituee d'un sel de tiotropium et de ciclesonide

Country Status (8)

Country Link
EP (1) EP1333830A2 (fr)
JP (1) JP2004512359A (fr)
AU (1) AU2002210575A1 (fr)
CA (2) CA2733294C (fr)
MX (1) MXPA03003751A (fr)
PE (1) PE20020576A1 (fr)
UY (1) UY26992A1 (fr)
WO (1) WO2002036106A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
WO2002012266A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
DE10216429A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
US7084153B2 (en) 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040102469A1 (en) * 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
ATE474601T1 (de) 2004-05-31 2010-08-15 Almirall Sa Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CA2568834A1 (fr) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments pour inhalation comprenant des steroides et un anticholinergique
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CL2008000500A1 (es) 2007-02-19 2008-09-05 Cipla Ltd Combinacion farmaceutica que comprende una combinacion de dos o mas broncodilatadores o una combinacion de al menos un broncodilatador y al menos un corticosteroide; uso para tratar o prevenir una enfermedad respiratoria; e inhalador que comprende di
EP2100598A1 (fr) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
TR200909792A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909793A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909789A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, budesonid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
FI4188327T3 (fi) 2020-07-31 2025-07-25 Chemo Res S L Yhdistelmähoito inhalaatioannosteluun

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations

Also Published As

Publication number Publication date
UY26992A1 (es) 2002-06-20
MXPA03003751A (es) 2004-10-15
WO2002036106A2 (fr) 2002-05-10
EP1333830A2 (fr) 2003-08-13
AU2002210575A1 (en) 2002-05-15
CA2733294C (fr) 2011-12-20
JP2004512359A (ja) 2004-04-22
WO2002036106A3 (fr) 2002-09-19
CA2733294A1 (fr) 2002-05-10
CA2436540A1 (fr) 2002-05-10
PE20020576A1 (es) 2002-08-09

Similar Documents

Publication Publication Date Title
CA2436540C (fr) Composition pharmaceutique a base d'anticholinergiques et de corticosteroides
CA2431565C (fr) Nouvelles compositions pharmaceutiques a base d'anticholinergiques et de ciclesonide
US20120189556A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
AU2007202303B2 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
CA2440699C (fr) Composes destines au traitement de maladies inflammatoires
US20030018019A1 (en) Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20090088408A1 (en) Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20020193392A1 (en) Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
US7084153B2 (en) Medicaments comprising steroids and a novel anticholinergic
US20040228805A1 (en) Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
US20040161386A1 (en) Pharmaceutical compositions based on anticholinergic and dopamine agonists
CA2481268C (fr) Medicaments comprenant des steroides et un nouvel anticholinergique
US20030203918A1 (en) Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound
US20020193394A1 (en) Compounds for treating inflammatory diseases
CA2568834A1 (fr) Medicaments pour inhalation comprenant des steroides et un anticholinergique
AU2004262901B2 (en) Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
US20060110329A1 (en) Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid
CA2614631C (fr) Compositions pharmaceutiques contenant des anticholinergiques et des corticosteroides sous la forme d'une suspension ou d'une solution inhalable
CA2582153A1 (fr) Medicaments administres par inhalation contenant un nouvel anticholinergique, du formoterol et un steroide
CA2430592C (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'agonistes de la dopamine
CA2533792C (fr) Medicaments d'inhalation contenant des steroides et des esters d'acide carboxylique de fluorene

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201023